High Intraindividual Variability of Global Myocardial 18F-FDG Uptake over Time
==============================================================================

* Klaus Zöphel
* Joerg Kotzerke

**TO THE EDITOR:** Recently, Inglese et al. documented an extreme variability in the spatial and temporal heterogeneity of regional myocardial uptake on repeated whole-body 18F-FDG PET/CT in fasting oncologic patients without heart disease (*1*). The authors cautiously attributed uptake defects on myocardial 18F-FDG imaging to scar tissue, unless the defects are associated with severe hypoperfusion on 18F-FDG imaging used alone to evaluate myocardial viability. Furthermore, there are suggestions that 18F-FDG PET can detect radiation-induced myocardial damage early (e.g., in patients with esophageal cancer), but high myocardial 18F-FDG uptake corresponded to irradiated fields in only 20% of patients (*2*). In a case report, 18F-FDG PET/CT demonstrated an excellent concordance between increased myocardial 18F-FDG uptake and irradiated fields (*3*).

On the other hand, physiologic myocardial 18F-FDG uptake in fasting individuals free of any heart disease is controversial. Khandani et al. reported that a subjective visual determination of cardiac 18F-FDG uptake did not change significantly over time in 47 oncologic patients who underwent 4 to 9 serial PET scans (*4*). In contrast, de Groot et al. found that visual grading of myocardial 18F-FDG uptake changed significantly in nearly two thirds of 25 oncologic patients who underwent at least 3 serial PET scans (*5*).

We would like to report a 29-y-old man without evidence or a history of heart disease who showed an extremely high variability of global myocardial 18F-FDG uptake on 3 PET/CT scans. The patient was diagnosed with rhabdomyosarcoma of the right testis and underwent ablative surgery but still had multiple pulmonary and several lymphogenic metastases. The first 18F-FDG PET/CT scan was performed in October 2007 after 4 cycles of palliative chemotherapy and showed metastatic disease in the right and left lungs and inguinal lymph node involvement, but myocardial 18F-FDG uptake (maximal standardized uptake value [SUVmax], 2.7; mean [±SD] standardized uptake value [SUVmean], 1.6 ± 0.2) was comparable to the mediastinal background level. A second scan in January 2008 showed partial metabolic remission of these lung metastases after high-dose chemotherapy with carboplatin and etoposide followed by autologous stem cell transplantation in November 2007 but high global myocardial 18F-FDG uptake (SUVmax, 7.1; SUVmean, 4.5 ± 0.8). The patient had never received radiation treatment. Therefore, we did not observe radiation-related myocardial damage in the second PET/CT scan. Seven weeks later, in February 2008, the patient underwent the third PET/CT scan, which was performed because of suspected progressive disease under ongoing chemotherapy for consolidation but found metabolically (and morphologically) stable disease. The image showed myocardial 18F-FDG uptake comparable to the mediastinal background level of the first scan (SUVmax, 2.5; SUVmean, 1.5 ± 0.2). All routinely measured external parameters during the 3 scans were almost identical. The patient fasted at least 12 h before each examination. The blood glucose levels at the times of the first, second, and third scans were 6.0, 4.7, and 5.2 mmol/L, respectively, and the levels of creatinine (58 μmol/L at scan 1 and 54 μmol/L at scan 3) and TSH (1.85 mIU/L at scan 1 and 1.91 mIU/L at scan 3) were always within the reference range. The administered activities were 332, 313, and 317 MBq of 18F-FDG, and the scans started at 1 h 4 min, 59 min, and 59 min after injection. Of course, the reconstruction parameters for all images were identical. A 300% (!) increase in global myocardial 18F-FDG uptake occurred during the second scan.

It is still unclear to us why such an extremely high intraindividual variability in global myocardial 18F-FDG uptake can occur, but this variability underlines the necessity for further studies in this field. In this context, the set-up of Inglese et al. is only one side of the coin (*1*). The other side is to study modulation of glucose metabolism in myocytes for a better understanding of myocardial glucose metabolism (*6*), in particular after radiation treatment or stem cell transplantation (*7*).

## Footnotes

*   COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

## References

1.  1. Inglese E, Leva L, Matheoud R, et al. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. J Nucl Med. 2007;48:1662–1669.
    
    [Abstract/FREE Full Text](http://jnm.snmjournals.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Njoiam51bWVkIjtzOjU6InJlc2lkIjtzOjEwOiI0OC8xMC8xNjYyIjtzOjQ6ImF0b20iO3M6MjQ6Ii9qbnVtZWQvNDkvOS8xNTcwLjEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

2.  2. Jingu K, Kaneta T, Nemoto K, et al. The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. Int J Radiat Oncol Biol Phys. 2006;66:845–851.
    
    [PubMed](http://jnm.snmjournals.org/lookup/external-ref?access_num=17011456&link_type=MED&atom=%2Fjnumed%2F49%2F9%2F1570.1.atom) 

3.  3. Zöphel K, Hölzel C, Dawel M, Hölscher T, Evers C, Kotzerke J. PET/CT demonstrates increased myocardial FDG uptake following irradiation therapy. Eur J Nucl Med Mol Imaging. 2007;34:1322–1323.
    
    [CrossRef](http://jnm.snmjournals.org/lookup/external-ref?access_num=10.1007/s00259-007-0469-3&link_type=DOI) 
    
    [PubMed](http://jnm.snmjournals.org/lookup/external-ref?access_num=17546454&link_type=MED&atom=%2Fjnumed%2F49%2F9%2F1570.1.atom) 

4.  4. Khandani AH, Isasi CR, Donald Blaufox M. Intra-individual variability of cardiac uptake on serial whole-body 18F-FDG PET. Nucl Med Commun. 2005;26:787–791.
    
    [CrossRef](http://jnm.snmjournals.org/lookup/external-ref?access_num=10.1097/01.mnm.0000175264.33368.da&link_type=DOI) 
    
    [PubMed](http://jnm.snmjournals.org/lookup/external-ref?access_num=16096582&link_type=MED&atom=%2Fjnumed%2F49%2F9%2F1570.1.atom) 
    
    [Web of Science](http://jnm.snmjournals.org/lookup/external-ref?access_num=000231719000006&link_type=ISI) 

5.  5. de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32:98–101.
    
    [CrossRef](http://jnm.snmjournals.org/lookup/external-ref?access_num=10.1007/s00259-004-1670-2&link_type=DOI) 
    
    [PubMed](http://jnm.snmjournals.org/lookup/external-ref?access_num=15605289&link_type=MED&atom=%2Fjnumed%2F49%2F9%2F1570.1.atom) 
    
    [Web of Science](http://jnm.snmjournals.org/lookup/external-ref?access_num=000226516600013&link_type=ISI) 

6.  6. Lloyd S, Brocks C, Chatham JC. Differential modulation of glucose, lactate, and pyruvate oxidation by insulin and dichloroacetate in the rat heart. Am J Physiol Heart Circ Physiol. 2003;285:H163–H172.
    
    [Abstract/FREE Full Text](http://jnm.snmjournals.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiYWpwaGVhcnQiO3M6NToicmVzaWQiO3M6MTA6IjI4NS8xL0gxNjMiO3M6NDoiYXRvbSI7czoyNDoiL2pudW1lZC80OS85LzE1NzAuMS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

7.  7. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev. 2007;12:331–343.
    
    [CrossRef](http://jnm.snmjournals.org/lookup/external-ref?access_num=10.1007/s10741-007-9034-1&link_type=DOI) 
    
    [PubMed](http://jnm.snmjournals.org/lookup/external-ref?access_num=17516164&link_type=MED&atom=%2Fjnumed%2F49%2F9%2F1570.1.atom) 
    
    [Web of Science](http://jnm.snmjournals.org/lookup/external-ref?access_num=000248170900017&link_type=ISI)